Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors

Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors

[at noodls] – Granted Patents Provide Exclusivity for Potential Uses of Sapacitabine in Hematological Malignancies and Solid Tumors BERKELEY HEIGHTS, N.J., Feb. 12, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view

Share this post